drugset / Trial / NCT05759897
A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus
RandomizedParallel-groupDouble-blindOther
Summary
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in subjects with type 2 diabetes mellitus.
Timeline
- Start
- 2023-02-28
- Primary completion
- 2023-12-21
- Completion
- 2024-01-04
Outcome
Met primary endpoint
paper placebo-adjusted differences ranged from -0.94% (95% CI, -1.43% to -0.45%) to -1.57% (95% CI, -2.05% to -1.08%) (all P < .001). PMID 42234428 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRS-7535 | Small molecule | 15 mg | Oral |
| Subject | HRS-7535 | Small molecule | 30 mg | Oral |
| Subject | HRS-7535 | Small molecule | 60 mg | Oral |
| Subject | HRS-7535 | Small molecule | 90 mg | Oral |